Table 1. Summary of outcomes of interest, systematic review about screening of migrants for Trypanosoma cruzi .

Outcome	Number of studies	Quality of evidence	Impact
Patients with T. cruzi infection	26 observational studies [5-7,9,22-43]	Low	1. Total pooled prevalence: 6% (95% CI: 3–10); 2. Among immigrants in general: 13% (95% CI: 7–21; I2 =  98.15%) 3. Pregnant women: 4% (95% CI: 2–7; I2 = 96.28%) 4. Blood donors: 0.42% (95% CI: 0.03–1.08%; I2 = 82.06)
Vertical transmission of T. cruzi infection	13 observational studies [6,35-43,46,49,50]	Low	1. Pooled transmission rate: 3 per 100 live births (95% CI: 1–6; I2 = 21.40%) 2. Symptoms of infection in 20% (95% CI: 0–53; I2 = 32.4%)
Mild to moderate organ involvement: cardiovascular symptoms	9 observational studies [6,7,9,24,29,45-48]	Low	Cardiovascular disease: 19% (95% CI: 13–27%; I2 = 88.36%)
Mild to moderate organ involvement: digestive symptoms	9 observational studies [7,24,25,28,29,45-48]	Low	Gastrointestinal abnormalities: 5% (95% CI: 2–11; I2 = 89.62%)
Severe organ involvement	11 observational studies [6,7,9,24,25,28,29,45-48]	Low	1. Severe cardiac events: 1% (95% CI: 0–2; I2 = 57.9%) 2. Severe gastrointestinal involvement (megasyndrome): 0% (95% CI: 0–1; I2 = 41.26%)
Indication for treatment	11 observational studies [6,29,30,35,37,39,43,45-48]	Very low	1. Initiation of trypanocidal therapy: 81% (95% CI: 67–93; I2 = 93.25%) 2. End of treatment: 78% (95% CI: 65–89; I2 = 88.5%) 3. Treatment-related adverse effects: 47% (95% CI: 32–63; I2 = 90.45%)
Mortality	2 observational studies [6,7]	Low	Two reports of sudden cardiac death secondary to Chagas disease

CI: confidence interval.